StreetInsider.com News Articles

IMUNON agrees to sell ThermoDox rights to VoxelDox Therapeutics

Wed, 21 Oct 2026 08:16:02 -0400

IMUNON, Inc. (Nasdaq: IMNN) has agreed to sell its rights to ThermoDox®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc., according to a press release from the Lawrenceville, N.J.-based company.

Under the terms of the agreement, IMUNON will receive an equity stake of approximately 4.76% in VoxelDox, along with up to $16.5 million in contingent milestone payments and tiered royalties ranging from 3.5% to 6% on net sales of ThermoDox products, if approved. VoxelDox intends to develop ThermoDox for the treatment of glioblastoma multiforme, a form of brain cancer.

The transaction's closing is contingent on VoxelDox completing a planned $2.5

IMUNON agrees to sell ThermoDox rights to VoxelDox Therapeutics

Wed, 21 Oct 2026 08:16:02 -0400

The transaction's closing is contingent on VoxelDox completing a planned $2.5

Form 8-K Imunon, Inc. For: Oct 20

Wed, 21 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261021/27213528.html

IMUNON Announces Strategic Sale of ThermoDox®

Wed, 21 Oct 2026 08:15:00 -0400

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001

LAWRENCEVILLE, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an agreement to sell its rights to ThermoDox^®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. (“VoxelDox”). Under the agreement, VoxelDox intends

IMUNON Announces Strategic Sale of ThermoDox®

Wed, 21 Oct 2026 08:15:00 -0400

Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial

Sale Reinforces IMUNON's Commitment to Its Core Strategy: Executing the Pivotal Phase 3 OVATION 3 Trial of IMNN-001

Form 4 Imunon, Inc. For: Oct 09 Filed by: Tardugno Michael H

Tue, 13 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261013/27181172.html

Form 4 Imunon, Inc. For: Oct 09 Filed by: Lindborg Stacy

Tue, 13 Oct 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20261013/27181153.html

Form 4 Imunon, Inc. For: Oct 09 Filed by: Faller Douglas Vincent

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181111.html

IMUNON to Participate in Upcoming Investor Conferences

Thu, 08 Oct 2026 09:00:00 -0400

LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences.

Maxim Growth Summit 2026
Date: October 12 - 14, 2026
Location: Hard Rock Hotel, New York, NY
Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET

For more information and a complete agenda of the Maxim Growth Summit, please visit https://www.maximgrp.com/2026-growth-summit.

2026 ThinkEquity Conference
Date: October 15, 2026
Location: Mandarin Oriental Hotel, New York, NY
Presentation:

IMUNON to Participate in Upcoming Investor Conferences

Thu, 08 Oct 2026 09:00:00 -0400

Maxim Growth Summit 2026
Date: October 12 - 14, 2026
Location: Hard Rock Hotel, New York, NY
Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET

For more information and a complete agenda of the Maxim Growth Summit, please visit https://www.maximgrp.com/2026-growth-summit.

2026 ThinkEquity Conference
Date: October 15, 2026
Location: Mandarin Oriental Hotel, New York, NY
Presentation:

Imunon exchanges $1.2M in debt for Series B preferred stock

Tue, 29 Sep 2026 08:01:27 -0400

Imunon, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announced it has entered into an Exchange Agreement converting $1.2 million of outstanding debt, along with accrued and unpaid interest, into shares of newly designated Series B Preferred Stock.

Under the terms of the agreement, Imunon issued 120 shares of Series B Preferred Stock at a purchase price of $10,000 per share and a stated value of $12,000 per share. The shares were exchanged for principal and accrued interest outstanding under the company's A-1 Note. The transaction reduces the company's outstanding debt under the original note by approximately 43% and does not result

Form 8-K Imunon, Inc. For: Sep 28

Tue, 29 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27117777.html

IMUNON Converts $1.2 Million of Debt-to-Equity

Tue, 29 Sep 2026 08:00:00 -0400

Unique investment vehicle provides efficient access to equity capital
Outstanding debt of the original Note lowered by approximately 43%
No issuance of common stock or dilutive warrants

LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company’s newly designated, non-convertible Series B Preferred Stock. The transaction reduces the Company’s outstanding debt

IMUNON Converts $1.2 Million of Debt-to-Equity

Tue, 29 Sep 2026 08:00:00 -0400

Unique investment vehicle provides efficient access to equity capital
Outstanding debt of the original Note lowered by approximately 43%
No issuance of common stock or dilutive warrants

Form 4 Imunon, Inc. For: Sep 25 Filed by: Tardugno Michael H

Mon, 28 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260928/27114986.html

Form 4 Imunon, Inc. For: Sep 25 Filed by: Lindborg Stacy

Mon, 28 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260928/27114965.html

Form 4 Imunon, Inc. For: Sep 25 Filed by: Faller Douglas Vincent

Mon, 28 Sep 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260928/27114929.html

Imunon presents Phase 3 ovarian cancer trial data at R&D Day

Thu, 24 Sep 2026 08:05:19 -0400

Imunon, Inc. (Nasdaq: IMNN) presented updated clinical data for its IMNN-001 immunotherapy program at an R&D Day event, highlighting final overall survival results from its randomized Phase 2 OVATION 2 study in women with newly diagnosed advanced ovarian cancer.

In the 112-patient OVATION 2 trial, median overall survival was 45.1 months for patients receiving IMNN-001 plus neoadjuvant and adjuvant chemotherapy, compared with 30.4 months for standard of care alone, a difference of 14.7 months. In a subgroup receiving PARP inhibitor maintenance, median overall survival was 65.6 months versus 41.4 months for the control arm. The company noted the Phase 2 study

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

Thu, 24 Sep 2026 08:05:00 -0400

2026 R&D Day presentation highlights include:

Review of final Randomized Phase 2 overall survival results
Supportive Preliminary MRD Study Data and translational findings
Pathway to confirmatory readout in OVATION 3
Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis

LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagnosed advanced ovarian cancer. The program reviews final overall survival results from the randomized Phase 2

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

Thu, 24 Sep 2026 08:05:00 -0400

2026 R&D Day presentation highlights include:

Review of final Randomized Phase 2 overall survival results
Supportive Preliminary MRD Study Data and translational findings
Pathway to confirmatory readout in OVATION 3
Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis

IMUNON's Phase 2 ovarian cancer study cleared to continue after safety review

Tue, 22 Sep 2026 08:05:16 -0400

IMUNON, Inc. (Nasdaq: IMNN) announced that an Independent Data Monitoring Committee (IDMC) has reviewed all safety data from the company's ongoing Phase 2 minimal residual disease (MRD) study of IMNN-001 and recommended the trial continue without modification.

The IDMC, comprised of independent medical experts in gynecologic cancers, identified no new safety signals and confirmed comparable safety across both treatment arms. The committee also found no new safety concerns in the company's ongoing Phase 3 OVATION 3 trial.

The Phase 2 MRD study is a randomized, controlled trial assessing minimal residual disease in women with newly diagnosed advanced ovarian cancer following treatment with

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Tue, 22 Sep 2026 08:05:00 -0400

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date

No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy

MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting

Recommendation follows encouraging preliminary Phase 2 MRD data reported in July demonstrating evidence of deeper anti-tumor activity and immune activation

LAWRENCEVILLE, N.J., Sept.

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Tue, 22 Sep 2026 08:05:00 -0400

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date

No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy

MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting

Recommendation follows encouraging preliminary Phase 2 MRD data reported in July demonstrating evidence of deeper anti-tumor activity and immune activation

LAWRENCEVILLE, N.J., Sept.

Form 4 Imunon, Inc. For: Sep 11 Filed by: Tardugno Michael H

Tue, 15 Sep 2026 12:43:00 -0400
si-local-file:///var/storage/secattach/20260915/27063878.html

Form 4 Imunon, Inc. For: Sep 11 Filed by: Lindborg Stacy

Tue, 15 Sep 2026 12:42:00 -0400
si-local-file:///var/storage/secattach/20260915/27063872.html